Jurassic Products: FDA Resurrects Withdrawn Drugs To Study Liver Injury
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency soliciting contractor to produce 37 drugs withdrawn because of liver injury; goal is developing better tools for evaluating compounds in the pipeline.
You may also be interested in...
FDA Liver Injury Conference Another Chance To Inform Guidance Changes
March event will look at best ways to detect and assess drug liver injury causation as agency mulls reopening the 2009 final guidance.
FDA Could Shift Assessment Of Drug-Induced Liver Injury In Clinical Trials
Agency officials, industry and academia contemplate a new approach to gauging drug-induced liver injury by using individual patients’ baseline liver enzyme measurements, a move that some say could eliminate problems with the use of the upper limit of normal and allow for the assessment of DILI in cases where there is underlying liver injury.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.